ArticleBlood2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.Blood advances · 2025Trial
- Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).British journal of haematology · 2025Trial
- Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.The oncologist · 2026Article
- Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.British journal of haematology · 2026Article
- Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.European journal of haematology · 2026Review
- Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.Blood advances · 2026Article
- Article
- Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.Hematology. American Society of Hematology. Education Program · 2025Article
- A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting TherapiesTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.HemaSphere · 2025Article
- Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.Blood advances · 2025Observational
- Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.Haematologica · 2025Article
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).Cancers · 2025Review
- Article
- Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.Haematologica · 2025Article
- Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.Biomarker research · 2025Article
- Review
- Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.Human vaccines & immunotherapeutics · 2024Article
Corrections and comments
- Commented on by
Authors and funding
24 authors at 12 institutions in 1 country.
David A QuallsLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5297-9685
Nicholas LambertDepartment of Medicine, Baylor College of Medicine, Houston, TX.
Paolo F CaimiDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.ORCID 0000-0003-1436-0464
Mwanasha MerrillDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4316-6938
Priyanka PullarkatDivision of Hematology-Oncology, Massachusetts General Hospital, Boston, MA.
Richard C GodbyHematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
David A BondDivision of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.ORCID 0000-0003-0773-1829
Graham T WehmeyerDepartment of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.ORCID 0000-0003-2321-1970
Jason RomancikDepartment of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA.ORCID 0000-0003-0054-9362
Behzad AmoozgarDepartment of Medicine, Washington University School of Medicine, St Louis, MO.
Lori LeslieLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
Loretta J NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6071-8610
Jennifer L CrombieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-3445-5129
Jeremy S AbramsonDivision of Hematology-Oncology, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-8467-9257
Arushi KhuranaHematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Grzegorz S NowakowskiHematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Kami MaddocksDivision of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.
Sarah C RutherfordDepartment of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
Brad KahlDepartment of Medicine, Washington University School of Medicine, St Louis, MO.
Michelle OkwaliLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael J BuegeLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9063-1495
Venkatraman SeshanLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9258-2698
Connie L BatleviLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9036-9463
Gilles SallesLymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9541-8666
Memorial Sloan Kettering Cancer Center · USMayo Clinic · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USNewYork–Presbyterian Hospital · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USWashington University in St. Louis · USBaylor College of Medicine · USCleveland Clinic · USEmory University · USHackensack University Medical Center · USThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058
Abstract
abstractIn this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
Indexed as
Lymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedLenalidomidetafasitamab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.